Istanbul Medeniyet University
medeniyet.edu.trTotal trials
180
Active
22
Phase 3
1
Total enrollment
36,660
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Transcutaneous Spinal Direct Current Stimulation and Transcranial Direct Current Stimulation | — | — | — | — | — | 1 | |
| Sham ts-DCS and sham t-DCS | — | — | — | — | — | 1 | |
| Standard COPD Pharmacological Therapy | — | — | — | — | — | 1 |
Next readouts
- 2024-05-15
- 2025-06-30
Top conditions
- Stroke8
- Anxiety6
- Procedural Pain5
- Pain5
- Exercise4
- Multiple Sclerosis4
- Healthy4
- Psoriasis Vulgaris4
Frequently asked questions about Istanbul Medeniyet University
- How many clinical trials does Istanbul Medeniyet University have on ClinicalTrials.gov?
- Istanbul Medeniyet University is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Istanbul Medeniyet University's trials are in Phase 3?
- 1 of Istanbul Medeniyet University's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Istanbul Medeniyet University focus on?
- Istanbul Medeniyet University's most-studied conditions on ClinicalTrials.gov are Stroke, Anxiety, Procedural Pain, Pain, Exercise.
- When are Istanbul Medeniyet University's next clinical trial readouts?
- Istanbul Medeniyet University has 2 upcoming primary-completion readouts tracked here; the soonest is “The Effects of Two Types of t-DCS Stimulation on Robot-assisted Gait Training in Patients With Multiple Sclerosis”, expected around 2024-05-15.